1 |
Identification of CD47 as a novel therapeutic target for hepatocellular carcinomaCheung, Chi-ho., 張志豪. January 2011 (has links)
published_or_final_version / Pathology / Master / Master of Philosophy
|
2 |
Generation of multivalent recombinant MVA vaccines for malariaOrubu, Toritse January 2012 (has links)
Modified vaccinia virus Ankara (MVA) has been used extensively as a recombinant vector for delivery of antigens from diverse pathogens. Its ability to generate strong antigen specific CD8+ T cell responses in humans has been shown in clinical trials of novel vaccines against malaria, tuberculosis, HIV I AIDS, influenza and cancer. The work in this thesis describes the use of BAC recombineering technology to harness the endogenous regulatory signal (promoter) that drives the expression of non-essential open reading frames (ORFs) in MVA for immunogenic expression of a recombinant antigen. Replacement of the ORFs of four non-essential genes in MVA; C11R, F11l, A44L and B8R with an epitope tagged luciferase positioned to use the same endogenous promoter showed early transgene expression equal to or slightly higher than traditional p7.5 and short synthetic promoter (SSP) constructs. The frequency of antigen-specific CD8+ T cell induced in mice by single dose MVA or adenovirus-prime, rMVA-boost vaccination showed equivalent or slightly higher responses by the endogenous promoters compared to the traditional p7.5 and SSP constructs. Assessment of the growth rate of these viruses showed they were unimpaired and the insertions were genetically stable. Furthermore, the endogenous promoter driven insertion loci of B8R and C11R were used for the construction of a bivalent MVA expressing an epitope tagged luciferase (rLucPb9) and a Photinus pyralis (pLuc) luciferase. The frequency of antigen-specific CD8+ T cells induced in mice by bivalent MV A was equivalent to single-pLuc and single-Pb9 recombinants co-administered as a mixture, at separate sites or administered alone following single dose MV A vaccination but slightly lower for Pb9-specific CD8+ T cell following adenovirus-prime, rMVA-boost.
|
3 |
A study of MRP1-drug interactions : identification of the drug binding site(s)Daoud, Roni N. January 2000 (has links)
No description available.
|
4 |
Roles of TLR5 and ICOS on the human allogenic CD40-activated B cell-induced CD4hiCD25+ regulatory T cellsChan, Ping-lung., 陳秉隆. January 2011 (has links)
published_or_final_version / Paediatrics and Adolescent Medicine / Doctoral / Doctor of Philosophy
|
5 |
A study of MRP1-drug interactions : identification of the drug binding site(s)Daoud, Roni N. January 2000 (has links)
Over-expression of either P-gp1 and/or MRP1 in tumor cell lines confers resistance to structurally diverse anti-cancer drugs. Although the role of these two proteins in clinical drug resistance remains to be confirmed, the use of Pgp1-specific inhibitors in combination with standard anti-cancer drugs have demonstrated significant improvement in clinical response. However, evidence exists that reversal of P-gp1 alone is not sufficient. Therefore, while no drugs are currently available that can efficiently reverse MRP1 drug efflux in tumor cells, there is an urgent need to develop MRP1-specific blockers. In an effort to gain a better understanding of MRP1-drug interactions and to identify sequences within MRP1 that interact directly with drugs, we developed two structurally diverse photosensitive drug analogues, a quinoline-based compound (IACI) and a xanthone-derivative (IAARh123). Both compounds photolabeled MRP1 and showed a direct and specific interaction with the protein at physiologically relevant sites. Initial mapping of photolabeled sequences in MRP1 (Chapters 2 and 3), identified multiple IACI- or IAARh123-photolabeled peptides (∼4--7 kDa) derived from both the N-terminal (MSD0+MSD1+NBD 1) and C-terminal (MSD2+NBD2) domains of MRP1. A subsequent study (Chapter 4), using MRP1 variants with hemagglutinin (HA) epitopes inserted at eight different locations, led to a higher resolution mapping of the previously identified IACI- or IAARh123-labeled peptides. Specifically, two photolabeled peptides (∼6--7 kDa), derived from variants with insertions at positions 574 and 1222, were immunoprecipitated with anti-HA monoclonal antibody. Based on the location of the HA epitopes in the latter variants together with molecular masses of the two peptides, the photolabeled amino acid residues were localized to MRP1 sequences encoding transmembranes 10 and 11 of MSD1 and transmembranes 16 and 17 of MSD 2. Interestingly, the same sequences were photolabeled with both
|
6 |
Studies of CD44 variant isoform expression and function on activated human peripheral blood mononuclear cells and in renal transplantation /Varelias, Antiopi. January 2001 (has links) (PDF)
Thesis (Ph.D.)--University of Adelaide, Dept. of Medicine, 2001. / Errata slip inserted at back. "August 2001." Includes bibliographical references (leaves 254-296).
|
7 |
Structural and functional determinants of effective CD8⁺ T cell suppression of HIV-1 replicationSimons, Brenna Colleen. January 2009 (has links)
Thesis (Ph. D. in Microbiology and Immunology)--Vanderbilt University, May 2009. / Title from title screen. Includes bibliographical references.
|
8 |
Mechanism of endocytosis of CD33/Siglec-3 : role of ITIMs, tyrosine phosphorylation, and monoubiquitylation /Walter, Roland Bruno, January 2006 (has links)
Thesis (Ph. D.)--University of Washington, 2006. / Vita. Includes bibliographical references (leaves 121-132).
|
9 |
Functional characterization and therapeutic implication of CD47 in sorafenib resistance in hepatocellular carcinomaLo, Jessica, 盧姵岐 January 2014 (has links)
abstract / Pathology / Master / Master of Philosophy
|
10 |
Expression and mutations of fas gene in oesophageal cancerLee, Ping-yin., 李炳賢. January 2003 (has links)
published_or_final_version / Medical Sciences / Master / Master of Medical Sciences
|
Page generated in 0.0484 seconds